MET and non-small cell lung carcinoma: Taken together, these results support cMet as a driver of Plk1 inhibitor resistance in epithelial NSCLC in vivo, and the findings suggest that co‐inhibition of Plk1 and cMet increases apoptosis, leading to tumor regression in NSCLC.